The jab, known as CoVac-1 was shown to produce a strong white blood cell -- or T-cell -- response in all 36 phase one trial participants.
AFP/Patrick Hertzog
T-cells are white blood cells that attack and neutralise whole infected cells. This is unlike an antibody response, provoked by traditional COVID-19 and other vaccines, which targets specific pathogens within the body directly. Participants in the trial were between 18 and 80 years old and received a single dose of the vaccine.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: